Financial Performance - For the three months ended March 31, 2023, the company reported revenue of RMB 142,544,000, a decrease of 26.3% compared to RMB 193,367,000 for the same period in 2022[5] - Gross profit for the same period was RMB 100,789,000, down 37.8% from RMB 161,864,000 year-over-year[5] - Operating profit increased to RMB 67,224,000, compared to RMB 39,863,000 in the previous year, reflecting a growth of 68.7%[5] - Profit attributable to shareholders was RMB 52,388,000, representing a 55.8% increase from RMB 33,615,000 in the same quarter of 2022[5] - Basic earnings per share rose to 9.35 cents, up from 6 cents year-over-year[5] - Other income significantly increased to RMB 45,831,000 from RMB 5,701,000, marking a growth of 705.5%[5] - As of March 31, 2023, the company reported a net profit of RMB 52,388,000 for the three-month period, an increase from RMB 33,615,000 for the same period in 2022, representing a growth of approximately 55.8%[25] - The gross margin for the three months ended March 31, 2023, was approximately 70.7%, a decrease of 13% compared to 83.7% for the same period in 2022[28] Dividends and Shareholder Returns - The company did not recommend the payment of an interim dividend for the three months ended March 31, 2023, consistent with the previous year[24] - The board of directors proposed a special dividend of RMB 0.50 per share (before tax), totaling RMB 280,125,000, which is significantly higher than the RMB 35,015,625 distributed in the previous fiscal year[47] - The company plans to hold a special general meeting on June 2, 2023, to approve the proposed special dividend[47] Taxation and Financial Position - The effective corporate income tax rate for the company remains at 15% for the period, unchanged from the previous year[22] - The company’s income tax expense for the three months ended March 31, 2023, was RMB 14,810,000, compared to RMB 5,768,000 for the same period in 2022, indicating an increase in tax obligations[45] - The company's cash and bank balances totaled RMB 978,742,000 as of March 31, 2023, up from RMB 834,176,000 as of March 31, 2022, indicating a year-over-year increase of approximately 17.3%[31] - The unaudited consolidated net asset value of the company was approximately RMB 1,664,686,000 as of March 31, 2023, compared to RMB 1,487,364,000 as of March 31, 2022, reflecting a growth of about 11.9%[31] - As of March 31, 2023, the company's debt-to-asset ratio was 0.02%, down from 0.03% on March 31, 2022[57] Operational Developments - The company operates primarily in the manufacturing and distribution of traditional Chinese medicine and pharmaceutical products within China[12] - The company has successfully passed the consistency evaluation for its injectable product and has entered the seventh batch of national collection, indicating progress in product development and commercialization[29] - The company has officially commenced production in its small-volume injection workshops, increasing production capacity[53] - The company's product portfolio continues to expand, enhancing its R&D capabilities and market competitiveness[54] - The company maintained a stable financial position during the reporting period, with no significant fluctuations in production and material costs reported[28] Compliance and Governance - The financial results are unaudited and have been reviewed by the company's audit committee[19] - The company has adopted relevant guidelines for directors conducting securities transactions, ensuring compliance with GEM listing rules[64] - The company has not purchased, sold, or redeemed any of its listed shares during the reporting period[76] - The board believes that the foreign exchange risk has minimal impact on the group[56] Cost Management - The distribution and selling costs as a percentage of revenue for 2023 were 44.2%, a decrease of 2.6% from 46.8% in the same period last year[52] - Administrative expenses decreased from RMB 37,153,000 for the three months ending March 31, 2022, to RMB 16,387,000 in the same period of 2023[52]
吉林长龙药业(08049) - 2023 Q1 - 季度业绩